Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513244 | 0.85 | CHEK1 (0.60) | CHEK1BRD4SYKDRD2FEN1 | |
| SCHEMBL6519057 | 0.79 | CHEK1 (0.47) | CHEK1DRD2NPY1RMAPK8MAPK9 | |
| SCHEMBL6513681 | 0.77 | CHEK1 (0.70) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6521943 | 0.76 | CHEK1 (0.52) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6509246 | 0.76 | CHEK1 (0.55) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6514622 | 0.76 | CHEK1 (0.54) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6521937 | 0.76 | CHEK1 (0.52) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6514619 | 0.76 | CHEK1 (0.52) | CHEK1MAPK8MAPK9MAPK10KCNH2 | |
| SCHEMBL6510497 | 0.76 | CHEK1 (0.55) | CHEK1MAPK8MAPK9MAPK10 | |
| SCHEMBL6518538 | 0.75 | CHEK1 (0.67) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885BRD4 874/4885SYK 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.